Cure Ventures is pleased to welcome Gary Ruvkun, PhD, Nobel Laureate and Professor of Genetics at Harvard Medical School, as the keynote speaker at our 2026 Annual General Meeting.
Nobel Laureate Gary Ruvkun to Keynote Cure Ventures’ 2026 Annual General Meeting Read More »
The technology behind Tasca is complex and the process of forming and growing a company around it requires more than an investor signing a check.
Dr. Milenko Cicmil’s Story on How Tasca Came to Be Read More »
Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the closing of its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments.
Cure Ventures Launches with the Close of Inaugural $350 Million Fund Read More »
